Top Markets
#1 Black Phoenix Black Phoenix +732.42%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.50%
#3 MiL.k Alliance MiL.k Alliance +23.56%
#4 THORChain THORChain +21.03%
#5 Biconomy Biconomy +20.37%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +16.12%
#7 THORChain Yield THORChain Yield +15.47%
#8 MetaDAO MetaDAO +13.97%
#9 Moolah Moolah +12.70%
#10 Pons Pons +11.94%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Pell Bio-Med Technology Co., Ltd. Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd.

6949
Rank in Stocks #4991
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in... Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
Share Price
$47.38
Last synced: 2026-08-26
Market Cap
$3.11B
Change (1 day)
9.96%
Change (1 year)
238.59%
Country
TW
Trade Pell Bio-Med Technology Co., Ltd. (6949)

Category

Healthcare
Revenue for Pell Bio-Med Technology Co., Ltd. (6949)
Revenue in Aug 2026 TTM: 0
According to Pell Bio-Med Technology Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pell Bio-Med Technology Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH